Venus Remedies Share Price | Venus Remedies Stock Screener
VENUSREM
Pharmaceuticals
Share Price NSE
₹1715.10
▲
81.60 (5.00%)
Share Price BSE
₹1712.80
▼
-52.75 (-2.99%)
As of June 11, 2026, the Venus Remedies share price (NSE: VENUSREM) is ₹1,715.10 on NSE and ₹1,712.80 on BSE, up 5.00% from the previous close, with shares trading between ₹1,625.70 and ₹1,715.10, and a 52-week range of ₹428.15–₹1,715.10.
Analyse VENUSREM share price data and track historical price performance.
Use the Venus Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Venus Remedies Market Cap
₹2,618.59 Cr.
VENUSREM P/E Ratio (TTM)
25.30
Venus Remedies P/B Ratio
3.92
EPS (TTM)
₹76.89
Dividend Yield
0.51%
Debt to Equity
0.04
VENUSREM 52 Week High
₹1715.10
Venus Remedies 52 Week Low
₹428.15
Operating Margin
24.00%
Profit Margin
18.18%
VENUSREM Revenue (TTM)
₹264.00
EBITDA
₹68.00
Net Income
₹48.00
Total Assets
₹854.00
Total Equity
₹664.00
Venus Remedies Share Price Chart
Screen Venus Remedies share price with an interactive chart. Analyse VENUSREM price trends and volatility across different timeframes.
Venus Remedies Company Profile - Fundamental Screener
Screen Venus Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VENUSREM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE411B01019
Venus Remedies Balance Sheet Screener
Screen VENUSREM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 854 | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 |
| Current Assets | 395 | 452 | 360 | 323 | 278 | 234 | 294 | 265 | 260 | 259 |
| Fixed Assets | 283 | 229 | 219 | 216 | 241 | 262 | 289 | 364 | 389 | 406 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 28 | 19 | 60 | 58 | 47 | 58 | 96 | 137 | 159 | 180 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 664 | 561 | 488 | 460 | 440 | 400 | 323 | 333 | 362 | 389 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | 650 | 548 | 474 | 447 | 427 | 374 | 311 | 320 | 350 | 376 |
Venus Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Venus Remedies income statement and profit fundamentals.
Analyze VENUSREM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Venus Remedies share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 264 | 202 | 141 | 195 | 183 | 199 | 110 | 178 | 189 | 159 | 97 | 171 | 146 | 145 | 145 |
| Expenses | 196 | 166 | 122 | 162 | 143 | 176 | 97 | 163 | 159 | 131 | 85 | 150 | 131 | 137 | 129 |
| EBITDA | 68 | 36 | 19 | 33 | 40 | 23 | 13 | 16 | 30 | 28 | 13 | 21 | 14 | 8 | 16 |
| Operating Profit % | 24.00% | 15.00% | 11.00% | 16.00% | 21.00% | 10.00% | 10.00% | 4.00% | 10.00% | 16.00% | 11.00% | 11.00% | 8.00% | 4.00% | 10.00% |
| Depreciation | 7 | 5 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 8 | 8 | 6 | 7 | 8 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 62 | 31 | 13 | 27 | 34 | 18 | 7 | 9 | 25 | 20 | 5 | 14 | 8 | 0 | 8 |
| Tax | 14 | 10 | 3 | 6 | 8 | 7 | 6 | 6 | 5 | 9 | 4 | 4 | 1 | 0 | 1 |
| Net Profit | 48 | 21 | 10 | 20 | 26 | 11 | 1 | 4 | 20 | 11 | 1 | 10 | 7 | 0 | 7 |
| EPS | 35.53 | 15.71 | 7.18 | 15.06 | 19.14 | 7.86 | 0.92 | 2.63 | 14.66 | 8.27 | 0.88 | 7.44 | 5.13 | 0.17 | 5.16 |
Venus Remedies Cash Flow Screener - Liquidity Fundamentals
Screen VENUSREM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 86 | 37 | 37 | 41 | 132 | 78 | 45 | 31 | 59 | 47 |
| Investing Activities | -77 | -9 | -58 | -17 | 57 | -5 | -11 | 9 | -18 | 3 |
| Financing Activities | -1 | -1 | -1 | -10 | -162 | -73 | -35 | -39 | -44 | -46 |
| Net Cash Flow | 9 | 28 | -22 | 14 | 27 | 0 | -1 | 0 | -4 | 4 |
Venus Remedies Shareholding Pattern Screener
See Venus Remedies shareholding pattern with promoter, FII, and DII holdings.
Check Venus Remedies promoter holding and ownership changes for VENUSREM on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII Holding | 2.80% | 1.34% | 2.24% | 1.86% | 2.26% | 1.48% | 1.06% | 1.18% |
| DII Holding | 1.20% | 0.00% | 0.11% | 0.75% | 1.03% | 0.15% | 0.15% | 0.15% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 44.39% | 46.81% | 47.70% | 45.30% | 45.16% | 46.89% | 46.25% | 45.31% |
| Other Holding | 9.85% | 10.09% | 8.19% | 10.33% | 9.80% | 9.73% | 10.78% | 11.61% |
| Shareholder Count | 18,403 | 19,982 | 19,307 | 17,725 | 18,606 | 19,913 | 19,614 | 19,557 |
Venus Remedies Share Dividend Screener - Share Yield Analysis
Check Venus Remedies dividend history with payout and yield data.
View Venus Remedies dividend details including ex-dates and amounts for VENUSREM stock.
Venus Remedies Stock Index Membership
See which indices include Venus Remedies stock.
Check VENUSREM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Venus Remedies Market Events Screener - Corporate Actions
Get Venus Remedies corporate actions including splits, bonuses, and buybacks.
Check Venus Remedies stock events that may affect VENUSREM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 0.93% | ||
| 2026-08-20 | 2026-08-20 | Annual General Meeting | NA | 71.27% |
| 2026-05-26 | 2026-05-26 | Quarterly Result Announcement | NA | 20.91% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -3.15% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 1.78% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 14.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -2.92% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.36% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -1.96% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -0.66% |
Venus Remedies Competitors Screener - Peer Comparison
Screen VENUSREM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,315 | 38.82 | 58,220 | 6.38% | 11,565 | 62.37 |
| Divis Laboratories | 176,430 | 69.38 | 10,560 | 8.73% | 2,520 | 52.31 |
| Torrent Pharmaceuticals | 156,727 | 71.51 | 13,886 | 20.34% | 2,138 | 56.90 |
| Cipla | 119,140 | 30.13 | 29,045 | 2.24% | 3,870 | 65.46 |
| Dr Reddys Laboratories | 114,847 | 27.10 | 33,593 | -0.44% | 3,998 | 69.37 |
| Zydus Life Science | 112,336 | 21.63 | 26,720 | 13.65% | 5,242 | 61.62 |
| Lupin | 109,037 | 20.00 | 27,488 | 19.98% | 5,345 | 58.20 |
| Mankind Pharma | 103,519 | 52.44 | 14,278 | 12.03% | 1,750 | 57.08 |
| Aurobindo Pharma | 91,302 | 25.78 | 33,385 | 3.21% | 3,376 | 67.06 |
| Laurus Labs | 79,915 | 88.02 | 6,868 | 22.01% | 890 | 64.65 |
Venus Remedies Company Announcements - News Screener
Screen VENUSREM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-02 | Closure of Trading Window | - |
| 2026-06-16 | Social Media Post To Aware Shareholders To Update Their KYC. | - |
| 2026-06-04 | Venus Remedies Limited Secures Renewal Of Prestigious DSIR In-House R&D Recognition. | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-26 | Corporate Action-Board to consider Dividend | - |
| 2026-05-26 | Adoption Of MOA & AOA As Per The Companies Act 2013 | - |
| 2026-05-26 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-26 | Announcement under Regulation 30 (LODR)-Dividend Updates | - |
| 2026-05-26 | Financial Results For The Financial Year 2025-26. | - |
| 2026-05-26 | Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2026 | - |
| 2026-05-22 | Venus Remedies Receives Saudi FDA Approval For Plerixafor - Its First Maketing Authorization For The Specialty Oncology Therapy Globally | - |
| 2026-05-21 | Social Media Post On KYC Updation | - |
| 2026-05-15 | Corporate Action-Board to consider Dividend | - |
| 2026-05-15 | Board Meeting Intimation for Board Meeting Scheduled For 26Th May 2026. | - |
| 2026-05-06 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-04 | Disclosure Of Social Media Post On Transfer Of Physical Shares. | - |
| 2026-04-08 | Social Media Post | - |
| 2026-04-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-04 | Disclosures Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | - |